THERAGEN ETEX CO.,LTD. Logo

THERAGEN ETEX CO.,LTD.

A biotech and pharma group for genome-based personalized and precision medicine.

066700 | KO

Overview

Corporate Details

ISIN(s):
KR7066700006
LEI:
Country:
South Korea
Address:
경기도 안산시 단원구 산단로 68번길 58(초지동), 안산시

Description

THERAGEN ETEX CO.,LTD. is a biotechnology and pharmaceutical group focused on genome-based personalized and precision medicine. The company integrates advanced genomic analysis with pharmaceutical development and manufacturing. Its genomics division provides comprehensive genetic analysis services, leveraging pioneering achievements such as creating the world's first female and tiger genome maps and commercializing Asia's first individual genome analysis service. The pharmaceutical division develops and supplies medicines from its international GMP-certified facilities. The R&D pipeline focuses on incrementally modified drugs, orphan drugs, and novel anticancer therapies, including its proprietary drug candidate, Vactosertib, which is in clinical trials for various cancers.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-21 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-03-21 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB
2025-03-19 00:00
감사보고서제출
Korean 27.5 KB
2025-03-19 00:00
사업보고서 (2024.12)
Korean 519.0 KB
2025-03-14 00:00
증권발행결과(자율공시)
Korean 6.4 KB
2025-03-14 00:00
최대주주변경
Korean 27.6 KB
2025-03-10 00:00
주주총회소집공고
Korean 172.1 KB
2025-03-10 00:00
의결권대리행사권유참고서류
Korean 170.3 KB
2025-03-10 00:00
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 17.4 KB
2025-03-06 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 47.5 KB
2025-03-06 00:00
주주총회소집결의
Korean 11.1 KB
2025-03-06 00:00
주주총회집중일개최사유신고
Korean 4.4 KB
2025-02-26 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 12.0 KB
2025-02-14 00:00
소송등의판결ㆍ결정
Korean 5.3 KB
2025-02-12 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 40.8 KB

Automate Your Workflow. Get a real-time feed of all THERAGEN ETEX CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for THERAGEN ETEX CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for THERAGEN ETEX CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.